Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Luron Fleming

Nurse Practitioner, Psychiatric/Mental Health Greenville, SC Nurse Practitioner

NPI 1376172502 CMS profile 10431012

712 Arlington Ave, Greenville, SC 29601

Open in the dashboard

General payments

$61,325

669 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luron Fleming of Greenville, SC is reported in the CMS Open Payments database as having received $61,325 across 669 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,717 121
2024 General $21,787 140
2023 General $3,142 127
2022 General $2,245 122
2021 General $2,434 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luron Fleming
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Luron Fleming were reported at $31,717. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Luron Fleming Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,434 $166 $54–$482 $132
2022 $2,245 $195 $66–$559 $149
2023 $3,142 $233 $82–$673 $160
2024 $21,787 $236 $84–$688 $164
2025 $31,717 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axsome Therapeutics, Inc. $47,555 109 payments
  2. AbbVie, Inc. $4,498 158 payments
  3. ITI, Inc. $1,402 45 payments
  4. Otsuka America Pharmaceutical, Inc. $1,317 64 payments
  5. Supernus Pharmaceuticals, Inc. $1,037 16 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $717 45 payments
  7. Sunovion Pharmaceuticals Inc. $600 30 payments
  8. Janssen Pharmaceuticals, Inc $543 26 payments
  9. Alkermes, Inc. $498 20 payments
  10. Vanda Pharmaceuticals Inc. $485 25 payments
  11. Other $2,673 131 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Honoraria $20,125 11 payments
  2. Consulting Fee $15,375 12 payments
  3. Food and Beverage $14,528 621 payments
  4. Travel and Lodging $9,137 20 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 2 payments
  6. Education $159 3 payments
Products named General payments · program years 2021–2025
  1. Auvelity $47,555 109 payments
  2. VRAYLAR Neuroscience $2,309 136 payments
  3. VRAYLAR Neuroscience $2,147 18 payments
  4. REXULTI $1,260 60 payments
  5. CAPLYTA $1,156 39 payments
  6. TRINTELLIX $717 45 payments
  7. Qelbree $709 8 payments
  8. LATUDA $600 30 payments
  9. FANAPT $485 25 payments
  10. HETLIOZ $415 24 payments
  11. Other $5,771 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,352

Median for Nurse Practitioner: 389

Drug cost

$114,543

Median for Nurse Practitioner: $21,885

Branded share of claims

23.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lybalvi Olanzapine/Samidorphan Malate Brand 15 $23,660
Caplyta Lumateperone Tosylate Brand 12 $23,094
Auvelity Dextromethorphan Hbr/Bupropion Brand 24 $20,104
Rexulti Brexpiprazole Brand 12 $16,603
Vyvanse Lisdexamfetamine Dimesylate Brand 16 $6,637
Fluvoxamine Maleate Er Fluvoxamine Maleate Brand 18 $5,337
Quetiapine Fumarate Generic 105 $2,070
Atomoxetine Hcl Generic 11 $1,462
Fluoxetine Hcl Generic 53 $1,151
Paliperidone Er Paliperidone Brand 12 $1,069

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$6,626

Medicare's payments for the services billed

Medicare patients

17

Average age 63

Services billed

134

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$18,666 24 —
Qelbree
$677 — —
VRAYLAR
$618 — —
CAPLYTA
$518 12 —
REXULTI
$313 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

669 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record